1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Defence Therapeutics Inc.
  6. Summary
    DTC   CA24463V1013

DEFENCE THERAPEUTICS INC.

(DTC)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed Canadian National Stock E…
05/12/2022 05/13/2022 05/18/2022 05/19/2022 05/20/2022 Date
3(c) 3(c) 2.9(c) 3.2(c) 3.25(c) Last
3 100 3 850 22 282 19 391 10 638 Volume
0.00% 0.00% -3.33% +10.34% +1.56% Change
More quotes
Estimated financial data (e)
Sales 2020 - - -
Net income 2020 -0,67 M -0,52 M -0,52 M
Net cash position 2020 1,87 M 1,45 M 1,45 M
P/E ratio 2020 -
Yield 2020 -
Sales 2021 - - -
Net income 2021 -2,86 M -2,23 M -2,23 M
Net cash position 2021 5,45 M 4,25 M 4,25 M
P/E ratio 2021 -65,6x
Yield 2021 -
Capitalization 119 M 92,4 M 92,4 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float 93,9%
More Financials
Company
Defence Therapeutics Inc. is a Canada-based biotechnology company. The Company’s principal business activity is the development of a biological drug enhancer platform for biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company is engaged in developing the vaccines and antibody drug conjugates (ADC) products. Its Accum Technology platform provides drug... 
More about the company
All news about DEFENCE THERAPEUTICS INC.
05/18Defence?s novel accuvac-pte7 vaccine shows complete protection from cervical cancer
EQ
05/18Defence Therapeutics Inc.'s Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from C..
CI
04/07Defence therapeutics announces issuance of a u.s. patent covering its pioneering vaccin..
EQ
03/22DEFENCE THERAPEUTICS : An anti-cancer solutions platform company advancing its versatile a..
EQ
03/22Defence Therapeutics Inc. Provides an Overview of Its Current Research and Development ..
CI
02/28Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
02/28DEFENCE THERAPEUTICS INC. : Defence releases peer-reviewed publication of its preclinical ..
EQ
02/28Defence Therapeutics Inc. Releases Peer-Reviewed Publication of Its Preclinical Data on..
CI
02/16DEFENCE THERAPEUTICS INC. : Defence retains cato sms to advise on its phase i clinical tri..
EQ
01/26DEFENCE THERAPEUTICS INC. : Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) acti..
EQ
01/26Defence Therapeutics Inc. Announces the Development of AccuVAC-PT009
CI
01/10Defence therapeutics achieves a major milestone and begins ind-enabling testing of its ..
EQ
01/10Defence Therapeutics Inc. Begins Ind-Enabling Testing of its Accutox Lead Compound Agai..
CI
2021Defence Therapeutics Inc. Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of CRIS..
CI
2021Defence therapeutics accumtm boosts by 9-fold the delivery effectiveness of the crispr/..
EQ
More news
News in other languages on DEFENCE THERAPEUTICS INC.
05/19DEFENCE THERAPEUTICS INC. : Defence Therapeutics Inc.: Gebärmutterhalskrebs-Impfstoff ACCU..
05/18DEFENCE THERAPEUTICS INC. : Der neuartige Impfstoff AccuVAC-PTE7 von Defence zeigt eine vo..
05/18DEFENCE THERAPEUTICS INC. : Der neuartige impfstoff accuvac-pte7 von defence zeigt eine vo..
05/18DEFENCE THERAPEUTICS INC. : Der neuartige impfstoff accuvac-pte7 von defence zeigt eine vo..
05/18Le nouveau vaccin AccuVAC-PTE7 de Defence Therapeutics Inc. démontre une protection com..
More news
Chart DEFENCE THERAPEUTICS INC.
Duration : Period :
Defence Therapeutics Inc. Technical Analysis Chart | DTC | CA24463V1013 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,25 CAD
Average target price 11,02 CAD
Spread / Average Target 239%
Managers and Directors
Sébastien Plouffe President, Chief Executive Officer & Director
P. Joseph Meagher Chief Financial Officer & Director
Raimar Löbenberg Chairman
Simon Beaudoin Chief Technology & Science Officer
Moutih Rafei Director & VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DEFENCE THERAPEUTICS INC.-39.81%92
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567